Protagenic therapeutics completes enrollment in single dose portion of phase 1 of innovative stress disorder trial

New york, ny / accesswire / may 1, 2024 / protagenic therapeutics, inc. (nasdaq:ptix), a leader in biopharmaceutical innovation, today announced the completion of enrollment in the single dose portion of its phase 1 trial involving pt00114, its synthetic stress-regulating peptide, for treating neuropsychiatric disorders. this marks a significant milestone with the enrollment of 30 subjects across five cohorts, receiving doses up to 1,000 micrograms.
PTIX Ratings Summary
PTIX Quant Ranking